PMID: 25773789Mar 17, 2015Paper

Clinical efficacy and possible applications of genomics in lung cancer

Asian Pacific Journal of Cancer Prevention : APJCP
Khalid Khalaf Alharbi

Abstract

The heterogeneous nature of lung cancer has become increasingly apparent since introduction of molecular classification. In general, advanced lung cancer is an aggressive malignancy with a poor prognosis. Activating alterations in several potential driver oncogenic genes have been identified, including EGFR, ROS1 and ALK and understanding of their molecular mechanisms underlying development, progression, and survival of lung cancer has led to the design of personalized treatments that have produced superior clinical outcomes in tumours harbouring these mutations. In light of the tsunami of new biomarkers and targeted agents, next generation sequencing testing strategies will be more appropriate in identifying the patients for each therapy and enabling personalized patients care. The challenge now is how best to interpret the results of these genomic tests, in the context of other clinical data, to optimize treatment choices. In genomic era of cancer treatment, the traditional one-size-fits-all paradigm is being replaced with more effective, personalized oncologic care. This review provides an overview of lung cancer genomics and personalized treatment.

References

Mar 16, 2004·Science·Yardena SamuelsVictor E Velculescu
Feb 25, 2005·The New England Journal of Medicine·Susumu KobayashiBalázs Halmos
Oct 3, 2007·The Journal of Clinical Investigation·Sophie SunJohn D Minna
Jul 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jussi P KoivunenPasi A Jänne
Aug 16, 2008·Genomics·Olena Morozova, Marco A Marra
Oct 25, 2008·Nature·Li DingRichard K Wilson
Nov 7, 2008·Nature·Timothy J LeyRichard K Wilson
Nov 19, 2008·Nature Reviews. Genetics·Zhong WangMichael Snyder
Feb 3, 2009·Proceedings of the National Academy of Sciences of the United States of America·Qi ZhaoRobert L Strausberg
Feb 28, 2009·Clinical Chemistry·Karl V VoelkerdingJacob D Durtschi
Jun 12, 2009·The New England Journal of Medicine·Sohrab P ShahDavid G Huntsman
Jul 14, 2009·Proceedings of the National Academy of Sciences of the United States of America·Christopher A MaherArul M Chinnaiyan
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Aug 12, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alice T ShawA John Iafrate
Aug 13, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Scott J RodigLucian R Chirieac
Aug 21, 2009·The New England Journal of Medicine·Tony S MokMasahiro Fukuoka
Nov 18, 2009·The Journal of Pathology·Daphne W Bell
Dec 18, 2009·Nature·Erin D PleasanceMichael R Stratton
Dec 25, 2009·Nature·Philip J StephensMichael R Stratton
Apr 27, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Takaaki SasakiPasi A Jänne
Jun 25, 2010·The New England Journal of Medicine·Makoto MaemondoUNKNOWN North-East Japan Study Group
Jul 9, 2010·CA: a Cancer Journal for Clinicians·Ahmedin JemalElizabeth Ward
Sep 9, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Chang-Qi ZhuMing-Sound Tsao
Sep 14, 2010·Nature Methods·Malachi GriffithMarco A Marra
Sep 17, 2010·Human Molecular Genetics·Li DingElaine R Mardis
Sep 18, 2010·Nature Reviews. Genetics·Matthew MeyersonGad Getz
Oct 15, 2010·The New England Journal of Medicine·Kimberly C WiegandDavid G Huntsman
Oct 29, 2010·The New England Journal of Medicine·Eunice L KwakA John Iafrate
Oct 29, 2010·Nature·Peter J CampbellP Andrew Futreal
Nov 12, 2010·The New England Journal of Medicine·Timothy J LeyRichard K Wilson
Dec 31, 2010·Nature Reviews. Genetics·Fatih Ozsolak, Patrice M Milos
Feb 1, 2011·The Lancet Oncology·William Pao, Nicolas Girard
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Nov 8, 2011·Clinics in Chest Medicine·Jill E Larsen, John D Minna
Jan 5, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kristin BergethonA John Iafrate

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.